$13.84
5.81% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US15102K1007
Symbol
CELC

Celcuity Inc. Stock price

$13.84
+0.99 7.70% 1M
-2.43 14.94% 6M
-0.73 5.01% YTD
-1.06 7.11% 1Y
+0.76 5.81% 3Y
+3.98 40.37% 5Y
-0.45 3.15% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
+0.76 5.81%
ISIN
US15102K1007
Symbol
CELC
Sector
Industry

Key metrics

Market capitalization $513.87m
Enterprise Value $347.00m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 3.43
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-96.57m
Free Cash Flow (TTM) Free Cash Flow $-74.47m
Cash position $264.06m
EPS (TTM) EPS $-2.61
P/E forward negative
Short interest 10.77%
Show more

Is Celcuity Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Celcuity Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Celcuity Inc. forecast:

8x Buy
100%

Analyst Opinions

8 Analysts have issued a Celcuity Inc. forecast:

Buy
100%

Financial data from Celcuity Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.12 0.12
25% 25%
-
-0.12 -0.12
25% 25%
-
- Selling and Administrative Expenses 7.51 7.51
60% 60%
-
- Research and Development Expense 89 89
67% 67%
-
-96 -96
66% 66%
-
- Depreciation and Amortization 0.12 0.12
25% 25%
-
EBIT (Operating Income) EBIT -97 -97
66% 66%
-
Net Profit -94 -94
66% 66%
-

In millions USD.

Don't miss a Thing! We will send you all news about Celcuity Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Celcuity Inc. Stock News

Neutral
GlobeNewsWire
18 days ago
Median overall survival (OS) among patients with HR+, HER2- advanced breast cancer who were treatment-naïve in the advanced setting was 77.3 months
Neutral
Seeking Alpha
about one month ago
Celcuity Inc. (NASDAQ:CELC ) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants Apoorva Chaloori - ICR Westwicke, Investor Relations Brian Sullivan - Co-Founder & Chief Executive Officer Vicky Hahne - Chief Financial Officer Conference Call Participants Maury Raycroft - Jefferies Brad Canino - Stifel Tara Bancroft - TD Cowen Chase Knickerbocker - Craig Hallum Ope...
Neutral
GlobeNewsWire
about one month ago
MINNEAPOLIS, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced financial results for the third quarter ended September 30, 2024 and other recent business developments.
More Celcuity Inc. News

Company Profile

Celcuity, Inc. is cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. Its proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Head office United States
CEO Brian Sullivan
Employees 55
Founded 2012
Website www.celcuity.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today